Navigation Links
ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
Date:12/18/2007

ical information or questions regarding the products all such inquiries shall be directed to Christo Shalish, cshalish@activbiotics.com, and/or Glenn Kazo, gkazo@activbiotics.com.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates" or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of ActivBiotics, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. For those statements, ActivBiotics, Inc. claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. ActivBiotics, Inc. will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
2. Exelixis Sells 80% Stake in Artemis to Taconic
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the continued ... an active venture capital market, leaders from BioCrossroads, ... Fund, Indiana University, Purdue University, the University of ... Suisse today announced the establishment of the INext ... funds. ,, Organized through BioCrossroads, Indiana,s initiative to ...
(Date:12/16/2009)... culture supplement? InVitria has what scientists have been asking for! ... improves the growth and productivity of CHO cells. Developed for ... animal free, well defined and consistent recombinant CHO supplement. ... ... 16, 2009 -- Scientists working with CHO cells can now ...
(Date:12/15/2009)... (JBEI), one of three Department of Energy (DOE) bio-energy ... to protect its valuable intellectual property. , ... ... 15, 2009 -- Surety, LLC , the leading ... announced that the Joint BioEnergy Institute (JBEI), one of ...
(Date:12/15/2009)... Va., Dec. 15 AstraZeneca (NYSE: ... of Virginia (UVa) in Charlottesville, today announced ... research collaboration to enhance development of new ... with a secondary focus on peripheral vascular ... ) ,, The collaborative preclinical research projects ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3
... 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical device company ... the spine, announced today,details relating to its fourth quarter ... on Tuesday, February 19, 2008, after,the close of the ... Tuesday, February 19, 2008 at,5:30 p.m. ET / 2:30 ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... of a second generation oral niacin receptor agonist,under a ... of atherosclerosis and other disorders. The initiation of this,trial ... very pleased with the progress of this collaboration,investigating the ...
... 24 ,Exelixis, Inc. (Nasdaq: EXEL ) announced today ... of Exelixis, will present at,the 2008 Wachovia Healthcare Conference ... January 31, 2008., The presentation will be webcast ... Investors on the Exelixis website at, http://www.exelixis.com ., ...
Other Biology Technology:NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
(Date:12/15/2009)... Extinct woolly mammoths and ancient American horses may ... several thousand years longer than previously thought. After ... Alaska, a team of researchers used cutting-edge techniques ... in permafrost samples dated to between 7,600 and ... at least one population of these now-extinct mammals ...
(Date:12/15/2009)... and economic toll on society. It is estimated that ... in U.S. waters and it,s likely that rip currents account ... disconnect exists between rip current research and public understanding. ... and more importantly, most people do not know how to ... The goal of the Rip Current Symposium is to identify ...
(Date:12/14/2009)... AlaskaScientists have identified a novel antifreeze molecule in a ... 100 degrees Fahrenheit. Unlike all previously described biological antifreezes ... little or no protein. It is composed of a ... new places within the cells of organisms. , ... this molecule is a whole new kind of antifreeze ...
Breaking Biology News(10 mins):Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4Scientists isolate new antifreeze molecule in Alaska beetle 2AIMS Benefit Solutions Offering Long Term Care Insurance Featuring CASH First 28TM 29 from United of Omaha 62932 1AIMS Benefit Solutions Offering Long Term Care Insurance Featuring CASH First 28TM 29 from United of Omaha 62932 2AIMS Benefit Solutions Offering Long Term Care Insurance Featuring CASH First 28TM 29 from United of Omaha 62932 3Your Online Resource For Plastic Surgery Information 62930 1Your Online Resource For Plastic Surgery Information 62930 2Statement of HDMA President and CEO John M Gray on the Importation of Prescription Drugs 62928 1Statement of HDMA President and CEO John M Gray on the Importation of Prescription Drugs 62928 2
... cells allow plants to build new organs throughout their ... and genetic factors work together to prevent plants from ... tumor-like. Scientists from the Max Planck Institute for Developmental ... growth-enhancing hormone and a regulatory protein, which controls the ...
... counterintuitive experiment has resulted in one of the longest ... new door for anti-aging research in humans. , Scientists ... of the SIR2 gene can promote longevity in yeast, ... widely and incorporated into anti-aging drug development programs at ...
... five New York flu seasons , On the eve of ... Research (TIGR) have captured influenza evolution in action. In a ... researchers report the first large-scale project to sequence the influenza ... evolving flu virus in a human population--and a new strategy ...
Other Biology News:Max Planck researchers make a breakthrough in plant stem cell research 2Max Planck researchers make a breakthrough in plant stem cell research 3New technique multiplies life span in simple organisms 2New technique multiplies life span in simple organisms 3First big influenza genome study reveals flu evolution 2First big influenza genome study reveals flu evolution 3First big influenza genome study reveals flu evolution 4